KTRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KTRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kintara Therapeutics's share price is $7.539. Kintara Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00. Hence, Kintara Therapeutics's PS Ratio for today is .
The historical rank and industry rank for Kintara Therapeutics's PS Ratio or its related term are showing as below:
Kintara Therapeutics's Revenue per Sharefor the three months ended in Jun. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00.
The historical data trend for Kintara Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Kintara Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
PS Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Kintara Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Kintara Therapeutics's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 7.539 | / | 0 | |
= |
Kintara Therapeutics's Share Price of today is $7.539.
Kintara Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
Kintara Therapeutics (NAS:KTRA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Kintara Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Hoffman | director, officer: President and CEO | ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121 |
Anthony Scott Praill | officer: Chief Financial Officer | 2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3 |
Saiid Zarrabian | director, officer: Head of Strategic Partnerships | P.O. BOX 675765, RANCHO SANTA FE CA 92067 |
Laura L. Johnson | director | C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122 |
Tamara A Seymour | director | C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008 |
Toth Robert Joseph Jr | director | 543 LOMBARD ST, SAN FRANCISCO CA 94133 |
Dennis M Brown | officer: Chief Scientific Officer | 100 SAN MATEO DR, MENLO PARK CA 94025 |
Keith Murphy | director | 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121 |
John Liatos | director, officer: SVP, Business Development | 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
John K Bell | director | 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8 |
Napoleone Ferrara | director | 550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101 |
Lynda Sarah Cranston | director | 4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3 |
Erich Mohr | director | 8300 GREENSBORO DRIVE, MCLEAN VA 22102 |
Jeffrey Bacha | director | SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
From GuruFocus
By PRNewswire • 04-10-2024
By PRNewswire • 09-11-2024
By GuruFocus Research • 02-07-2024
By PRNewswire • 10-16-2024
By PRNewswire • 09-09-2024
By PRNewswire • 10-14-2024
By ACCESSWIRE • 08-19-2024
By PRNewswire • 09-18-2024
By PRNewswire • 04-03-2024
By PRNewswire • 10-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.